FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.